Endeavor BioMedicines
Last verified 2026-05-20. JSON
| Total raised | $295.5M |
|---|---|
| Latest round | series-d+, $133.0M, 2024-04-01 |
| Founded | 2018 |
| Headquarters | San Diego, CA |
| Industry | biotechnology |
| Stage | series-b+ |
| Website | endeavorbiomedicines.com |
Endeavor BioMedicines is a clinical-stage biotech developing precision medicines for life-threatening diseases, led by taladegib (ENV-101) for idiopathic pulmonary fibrosis. It targets patients with fibrotic lung disease and, via a second program, HER3-positive solid tumors. Its lead IPF candidate is the first to receive PRIME designation and showed improved lung function while reversing disease markers in trials.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-04-01 | series-d+ | $133.0M | undisclosed |
Detected tech stack
Nginx, WordPress 7.0, Magnific Popup 1.1.0, Yoast SEO 27.5, Google Tag Manager, Slider Revolution, imagesLoaded 5.0.0, parallax.js, Plesk, OWL Carousel, Bootstrap, PHP
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series D+, $133.0M | sourced | SEC EDGAR named as publisher. Document, retrieved 2026-09-25. |
| Total raised $295.5M | sourced | SEC EDGAR named as publisher. Document, retrieved 2026-09-25. |
| Company existence | self-reported | endeavorbiomedicines.com, read 2026-05-20 |
| Description | self-reported | endeavorbiomedicines.com, read 2026-05-20 |
Change history
| Date | Fact | Change | Basis |
|---|---|---|---|
| 2026-09-25Round: attributed → sourced, SEC EDGAR, document, retrieved 2026-09-25 | Round | attributed → sourced | SEC EDGAR, document, retrieved 2026-09-25 |
Records begin 2026-09-24. All changes